Dramatic drop in new cancer drug trials during the COVID-19 pandemic

Data showing a 60% decrease in new clinical trials for cancer drugs and biological therapies during the pandemic further highlights the impact that COVID-19 is having on oncology research, leading organisations have warned. A comparison of trials launched between January and May, 2020, using information from the Medidata Enterprise Data Store found a dramatic decline compared with the previous 5 years. During the 40-month observation period,...